Korea FDA Issues Approval To Chong Kun Dang For Future Sales Of Generic Tamiflu
This article was originally published in PharmAsia News
Executive Summary
SEOUL - The Korea Food & Drug Administration granted approval to local South Korean Chong Kun Dang Pharmaceutical to sell its generic version of Roche's Tamiflu (oseltamivir) at some point in the future
You may also be interested in...
Roche Is Latest MNC To Partner A Primary Care Product In Korea
Handok, which is partially owned by Sanofi, will sell Roche’s Madopar for Parkinson’s disease in Korea.
Korea's Green Cross Gets Green Light From KFDA To Produce Novartis Adjuvanted A/H1N1 Vaccine
SEOUL - South Korean vaccine maker Green Cross said it has received the green light from Korea FDA to use Novartis's MF59 adjuvanted A/H1N1 vaccine for production of an A/H1N1 vaccine
South Korea Plans To Provide Tamiflu and Relenza To North Korea
SEOUL - With information on the spread of the A/H1N1 pandemic in North Korea closely guarded, the South Korean government is moving to supply the antiviral drugs Tamiflu and Relenza to workers in the North's Gaesung Industrial Zone as a gesture of compassion and reconciliation between the two Koreas